We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In a stunning mid-study analysis of 12 patients, GlaxoSmithKline’s anti-PD-1 antibody Jemperli (dostarlimab) completely eradicated locally advanced rectal tumors in every patient, sparing them life-altering surgery and causing minimal side effects. Read More
Breast cancer treatments by AstraZeneca (AZ)/Daiichi Sankyo and Gilead are grabbing headlines at the annual meeting of the American Society of Clinical Oncology this week. Read More
Johnson & Johnson’s (J&J) and AbbVie’s blockbuster cancer drug Imbruvica (ibrutinib) plus chemotherapy significantly slashed cancer spread in older patients suffering from mantle cell lymphoma (MCL) in a phase 3 study. Read More
Bristol Myers Squibb’s Orencia (abatacept) and Janssen’s Remicade (infliximab) reduced the risk of death among patients hospitalized with COVID-19 by around 40 percent, according to a study commissioned by the National Institutes of Health. Read More
Eight years after it shelved darapladib, GSK has sold the failed cardiovascular drug to startup SciNeuro Pharmaceuticals as a potential treatment for Alzheimer’s-associated cognitive decline. Read More
A two-week course of Sage Therapeutics’ investigational antidepressant zuranolone improved symptoms of postpartum depression as quickly as 3 days after initiating treatment, with the benefits sustained up to 45 days, the company said. Read More
The FDA has put the squeeze on Sanofi’s first steps toward an over-the-counter (OTC) version of Cialis (tadalafil), Eli Lilly’s once-blockbuster erectile dysfunction drug. Read More
In an effort to prepare for future health emergencies, the World Health Organization (WHO) has adopted a resolution geared toward delivering higher quality data and improving the conduct and coordination of clinical trials around the world. Read More
Zealand Pharma will bring a new form of its antihypoglycemia drug Zealogue (dasiglucagon) to the FDA as a potential treatment for children with congenital hyperinsulinism (CHI). Read More